ImmunoGen's cancer drug candidate IMGN901 received orphan-drug designation from U.S. and European regulators. The company is seeking to market the treatment for Merkel cell carcinoma, a form of skin cancer.
Published in Brief:
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.
ASAHI INTECC, Orange County CA R&D Center
|Santa Ana, CA|